Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
2025-03-26 Sale |
2025-03-27 7:19 pm |
Kalaris Therapeutics Inc. | KLRS | Hagen Brett R Chief Accounting Officer |
907 | $8.9693 | $8,135 | 1,925 (Direct) |
View |
2025-02-21 Sale |
2025-02-24 4:15 pm |
Allovir Inc. | ALVR | Sinha Vikas See Remarks 10% Owner |
303 | $10.08 | $3,053 | 774,118 (Indirect Direct) |
View |
2025-02-21 Sale |
2025-02-24 4:15 pm |
Allovir Inc. | ALVR | Hagen Brett R Chief Accounting Officer |
96 | $10.08 | $967 | 2,832 (Direct) |
View |
2025-02-21 Sale |
2025-02-24 4:15 pm |
Allovir Inc. | ALVR | Miller Edward General Counsel |
106 | $10.08 | $1,068 | 21,575 (Indirect Direct) |
View |
2025-01-23 Sale |
2025-01-27 4:16 pm |
Allovir Inc. | ALVR | Miller Edward General Counsel |
52 | $9.5006 | $494 | 21,681 (Indirect Direct) |
View |
2025-01-23 Sale |
2025-01-27 4:15 pm |
Allovir Inc. | ALVR | Hagen Brett R Chief Accounting Officer |
36 | $9.5078 | $342 | 2,928 (Direct) |
View |
2025-01-23 Sale |
2025-01-27 4:11 pm |
Allovir Inc. | ALVR | Sinha Vikas See Remarks 10% Owner |
129 | $9.5028 | $1,226 | 774,421 (Indirect Direct) |
View |
2025-01-10 Sale |
2025-01-13 4:15 pm |
Allovir Inc. | ALVR | Miller Edward General Counsel |
409 | $0.4401 | $180 | 499,889 (Indirect Direct) |
View |
2025-01-10 Sale |
2025-01-13 4:15 pm |
Allovir Inc. | ALVR | Hagen Brett R Chief Accounting Officer |
332 | $0.4401 | $146 | 68,174 (Direct) |
View |
2025-01-10 Sale |
2025-01-13 4:15 pm |
Allovir Inc. | ALVR | Sinha Vikas See Remarks 10% Owner |
979 | $0.4401 | $431 | 17,814,681 (Indirect Direct) |
View |
2024-11-19 Sale |
2024-11-20 4:15 pm |
Allovir Inc. | ALVR | Hagen Brett R Chief Accounting Officer |
554 | $0.5485 | $304 | 68,506 (Direct) |
View |
2024-11-19 Sale |
2024-11-20 4:15 pm |
Allovir Inc. | ALVR | Sinha Vikas See Remarks 10% Owner |
3,186 | $0.5485 | $1,748 | 17,815,660 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
2025-04-10 Option Award |
2025-04-11 5:27 pm |
N/A 2035-04-09 |
Kalaris Therapeutics Inc. | KLRS | Hagen Brett R Chief Accounting Officer |
50,262 | $0 | 50,262 (Direct) |
View |
2025-04-10 Option Award |
2025-04-11 5:20 pm |
N/A 2035-04-09 |
Kalaris Therapeutics Inc. | KLRS | AKKARAJU SRINIVAS Director 10% Owner |
18,000 | $0 | 18,000 (Direct) |
View |
2025-04-10 Option Award |
2025-04-11 5:08 pm |
N/A 2035-04-09 |
Kalaris Therapeutics Inc. | KLRS | Jovan-Embiricos Morana Director |
18,000 | $0 | 18,000 (Direct) |
View |
2025-04-10 Option Award |
2025-04-11 5:04 pm |
N/A 2035-04-09 |
Kalaris Therapeutics Inc. | KLRS | PATEL SAMIR CHANDRAKANT Director |
18,000 | $0 | 18,000 (Direct) |
View |
2025-04-10 Option Award |
2025-04-11 5:03 pm |
N/A 2035-04-09 |
Kalaris Therapeutics Inc. | KLRS | Ferrara Napoleone Director |
18,000 | $0 | 18,000 (Direct) |
View |
2025-04-10 Option Award |
2025-04-11 4:59 pm |
N/A 2035-04-09 |
Kalaris Therapeutics Inc. | KLRS | Dybbs Michael Director |
18,000 | $0 | 18,000 (Direct) |
View |
2025-04-10 Option Award |
2025-04-11 4:55 pm |
N/A 2035-04-09 |
Kalaris Therapeutics Inc. | KLRS | Oxtoby Andrew See Remarks |
287,000 | $0 | 287,000 (Direct) |
View |
2025-04-10 Option Award |
2025-04-11 4:52 pm |
N/A 2035-04-09 |
Kalaris Therapeutics Inc. | KLRS | ADAMIS ANTHONY P Director |
18,000 | $0 | 18,000 (Direct) |
View |
2025-04-10 Option Award |
2025-04-11 4:52 pm |
N/A 2035-04-09 |
Kalaris Therapeutics Inc. | KLRS | Feinsod Matthew Chief Medical Officer |
171,551 | $0 | 171,551 (Direct) |
View |
2025-04-10 Option Award |
2025-04-11 4:48 pm |
N/A 2035-04-09 |
Kalaris Therapeutics Inc. | KLRS | PATTERSON LEONE D Director |
18,000 | $0 | 18,000 (Direct) |
View |
2025-04-10 Option Award |
2025-04-11 4:41 pm |
N/A 2035-04-09 |
Kalaris Therapeutics Inc. | KLRS | Hallal David Director |
18,000 | $0 | 18,000 (Direct) |
View |
Ownership(A) |
2025-03-26 5:06 pm |
N/A N/A |
Kalaris Therapeutics Inc. | KLRS | AKKARAJU SRINIVAS Director 10% Owner |
0 | $0 | 3,578 (Indirect) |
View |
Ownership |
2025-03-25 7:38 pm |
N/A N/A |
Kalaris Therapeutics Inc. | KLRS | Samsara BioCapital GP LLC Samsara BioCapital L.P. 10% Owner |
0 | $0 | 11,448,081 (Indirect) |
View |
2025-03-18 Option Award |
2025-03-18 5:45 pm |
N/A N/A |
Kalaris Therapeutics Inc. | KLRS | Ferrara Napoleone Director |
504,000 | $0 | 504,000 (Direct) |
View |
2025-03-18 Option Award |
2025-03-18 5:44 pm |
N/A 2034-05-27 |
Kalaris Therapeutics Inc. | KLRS | PATEL SAMIR CHANDRAKANT Director |
458,713 | $0 | 458,713 (Direct) |
View |
2025-03-18 Option Award |
2025-03-18 5:43 pm |
N/A 2034-07-22 |
Kalaris Therapeutics Inc. | KLRS | Feinsod Matthew Chief Medical Officer |
32,254 | $0 | 32,254 (Direct) |
View |
2025-03-18 Option Award |
2025-03-18 5:41 pm |
N/A 2034-05-27 |
Kalaris Therapeutics Inc. | KLRS | Oxtoby Andrew See Remarks |
476,611 | $0 | 476,611 (Direct) |
View |
2025-03-18 Option Award |
2025-03-18 5:40 pm |
N/A N/A |
Kalaris Therapeutics Inc. | KLRS | AKKARAJU SRINIVAS Director 10% Owner |
11,444,503 | $0 | 11,444,503 (Indirect) |
View |
2025-03-18 Option Award |
2025-03-18 5:37 pm |
N/A 2032-07-25 |
Kalaris Therapeutics Inc. | KLRS | ADAMIS ANTHONY P Director |
32,473 | $0 | 32,473 (Direct) |
View |
2024-12-11 Gift |
2024-12-11 5:07 pm |
N/A N/A |
Allovir Inc. | ALVR | Miller Edward General Counsel |
57,549 | $0 | 500,298 (Direct) |
View |